EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility

Antonio Romero iD, Luke Ashcraft, Aroop Chandra, Vincent DiMassa, Peadar Cremin, Scott E Collibee, Chihyuan Chuang, James Hartman, Darren T Hwee, David St Jean, Justin Malinowski, Mikkel DeBenedetto und 8 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c02413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Antonio Romero und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Myocardial Contraction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen, Cytokinetics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac myosin activation has been shown to be a viable approach for the treatment of heart failure with reduced ejection fraction. Here, we report the discovery of nelutroctiv (CK-136), a selective cardiac troponin activator intended for patients with cardiovascular conditions where cardiac contractility is reduced. Discovery of nelutroctiv began with a high-throughput screen that identified compound 1R, a muscle selective cardiac sarcomere activator devoid of phosphodiesterase-3 activity. Optimization of druglike properties for 1R led to the replacement of the sulfonamide and aniline substituents which resulted in improved pharmacokinetic (PK) profiles and a reduced potential for human drug-drug interactions. In vivo echocardiography assessment of the optimized leads showed concentration dependent increases in fractional shortening and an improved pharmacodynamic window compared to myosin activator CK-138. Overall, nelutroctiv was found to possess the desired selectivity, a favorable pharmacodynamic window relative to myosin activators, and a preclinical PK profile to support clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial ContractionHumansAnimalsCardiovascular DiseasesRatsStructure-Activity RelationshipMaleDrug DiscoveryTroponinMiceRats, Sprague-DawleySulfonamides

Substanzen

TroponinSulfonamides

Autor:innen und Institutionen

  • Cytokinetics, Inc., 350 Oyster Point Boulevard, South San Francisco, California 94080, United States.

ORCID-Profile: Antonio Romero

Förderung

  • Amgen
  • Cytokinetics

Zitieren

APA

Romero, A., Ashcraft, L., Chandra, A., DiMassa, V., Cremin, P., Collibee, S. E., Chuang, C., Hartman, J., Hwee, D. T., St Jean, D., Malinowski, J., DeBenedetto, M., Moebius, D., Payette, J., Vargas, R., Yeoman, J., Motani, A., Reagan, J., Malik, F. I., & Morgan, B. P. (2024). Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02413

Vancouver

Romero A, Ashcraft L, Chandra A, DiMassa V, Cremin P, Collibee SE, et al. Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02413

BibTeX
@article{Romero2024,
  author = {Romero, Antonio and Ashcraft, Luke and Chandra, Aroop and DiMassa, Vincent and Cremin, Peadar and Collibee, Scott E and Chuang, Chihyuan and Hartman, James and Hwee, Darren T and St Jean, David and Malinowski, Justin and DeBenedetto, Mikkel and Moebius, David and Payette, Joshua and Vargas, Richard and Yeoman, John and Motani, Alykhan and Reagan, Jeffrey and Malik, Fady I and Morgan, Bradley P},
  title = {Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c02413}
}
Kostenlos starten →